Article

Laser system gets FDA clearance for anterior capsulotomy

The FDA has awarded 510(k) clearance to a proprietary laser system (LensAR, LensAR Inc.) for use for anterior capsulotomy during cataract surgery.

Winter Park, FL

-The FDA has awarded 510(k) clearance to a proprietary laser system (LensAR, LensAR Inc.) for use for anterior capsulotomy during cataract surgery.

"This is a critical milestone for the company. [It marks] our first cleared indication of what we believe will be many to come in this exciting new field of laser cataract surgery," said Randy Frey, founder and chief executive officer of LensAR.

The laser system integrates proprietary ocular measurement and three-dimensional laser scanning technologies with an advanced tissue-cutting laser.

"The capsulotomy is arguably the most critical and precise step in cataract surgery, and the ability to improve its sizing, centration, and consistency through automation is an important and exciting advance," said David F. Chang, MD, medical monitor for the company. He has used the laser system in Mexico.

Louis D. "Skip" Nichamin, MD, a member of the company's medical advisory board, also has had experience using the system. He said, "The application of femtosecond technology to cataract surgery is the most exciting development in ophthalmic surgery in decades. The increased precision of [this] technology can help in the improvement of surgical outcomes while assisting experienced and inexperienced surgeons achieve more consistent results."

For indications other than anterior capsulotomy during cataract surgery, the laser system is an investigational device in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.